DURECT (NASDAQ:DRRX) Issues Earnings Results

DURECT (NASDAQ:DRRX) released its quarterly earnings data on Wednesday. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.06 by ($0.12), Zacks reports. The business had revenue of $2.30 million during the quarter, compared to analysts’ expectations of $6.91 million. DURECT had a negative net margin of 198.58% and a negative return on equity of 300.62%.

DURECT Price Performance

DRRX remained flat at $0.81 on Thursday. 59,654 shares of the company were exchanged, compared to its average volume of 53,861. The stock’s 50-day simple moving average is $0.80 and its 200-day simple moving average is $1.01. The company has a market cap of $25.02 million, a PE ratio of -1.32 and a beta of 0.91. DURECT has a 52-week low of $0.70 and a 52-week high of $1.88.

Analyst Upgrades and Downgrades

DRRX has been the topic of a number of recent analyst reports. StockNews.com initiated coverage on DURECT in a research report on Thursday. They set a “sell” rating on the stock. HC Wainwright reissued a “neutral” rating on shares of DURECT in a research note on Thursday.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.